The Past Week's Notable Insider Buys: Amphenol, Aldeyra, Werewolf Therapeutics, And More

The Past Week's Notable Insider Buys: Amphenol, Aldeyra, Werewolf Therapeutics And More

Photo by Austin Distel on Unsplash.

Conventional wisdom says that insiders and 10% owners really only buy shares of a company for one reason — they believe the stock price will rise and they want to profit from it. So insider buying can be an encouraging signal for potential investors, particularly when there is uncertainty in the markets or the markets are near all-time highs.

Note that, with the earnings reporting season still underway, many insiders are prohibited from buying or selling shares. Here are some of the most noteworthy insider purchases that were reported in the past week.

A number of 10% owners of and directors at Werewolf Therapeutics Inc (HOWL) bought into its initial public offer last week. The more than 4.84 million shares they bought for $16.00 apiece totaled over $77.98 million altogether. Shares of this cancer-focused biopharma company closed the week's trading at $14.25 apiece.

The purchase of 1.20 million Aldeyra Therapeutics Inc (ALDX) shares by a beneficial owner came before last week's first-quarter report. At the public offering price of $12.50 per share, those transactions totaled $15.00 million. Note that the stock ended the week trading at $12.48 a share.

U.K.-based Vaccitech PLC saw a beneficial owner buy 600,000 shares and several other insiders pick up almost 146,900 altogether in this initial public offering. Though the offering price was $17.00 apiece, the shares went out at less than $14.00, and they ended the week at $13.53. These insider purchases added up to more than $12.37 million.

An Artisan Partners Asset Management Inc (APAM) director indirectly scooped up 98,000 shares of this Milwaukee-based asset manager recently. At prices ranging from $50.88 to $51.31 a share, the purchases totaled more than $5.00 million. The stock ended the last week trading up at $56.48 a share though.

A 10% owner added 185,800 more shares of AnaptysBio Inc (ANAB) last week to its stake, even though the San Diego-based biotech posted a first-quarter net loss. The shares were acquired indirectly for between $23.24 and $23.31 apiece, which totaled more than $4.32 million and lifted the owner's stake to more than 7.52 million shares.

1 2
View single page >> |

Disclaimer: At the time of this writing, the author had no position in the mentioned equities.

© 2021 Benzinga does not provide investment advice. All rights ...

How did you like this article? Let us know so we can better customize your reading experience.


Leave a comment to automatically be entered into our contest to win a free Echo Show.